MICS Centrum Medyczne Szczecin
- Address
- Ul. Andrzeja Struga 42, 70-784 Szczecin, Poland
Bacterial Infections and Mycoses
MICS Centrum Medyczne Szczecin is conducting research to improve prevention and treatment of bacterial and fungal diseases, including the evaluation of new vaccine strategies for children and adults.
- Safety and immunogenicity of a 21‑valent pneumococcal conjugate vaccine
- Assessment of novel antimicrobial agents for resistant infections
- Immune response profiling across different pediatric age groups
Findings from these studies aim to enhance public health protection and reduce the burden of serious infections.
Eye Diseases
The center is exploring innovative therapies for ocular conditions, with a focus on improving eyelid function and patient appearance.
- Evaluation of oxymetazoline eye drops for acquired blepharoptosis
- Safety monitoring of topical treatments for eyelid disorders
- Patient‑reported outcome measures for cosmetic improvement
By advancing non‑surgical options, the trials seek to provide a convenient solution for individuals affected by eyelid drooping.
Neoplasms
Research at the Szczecin site addresses a range of solid tumours, testing novel immunotherapy and targeted drug combinations to increase response rates in advanced cancers.
- Combination of a checkpoint inhibitor with investigational agents in solid tumours
- Comparison of an ALK inhibitor versus standard therapy in advanced lung cancer
- Antibody‑drug conjugate efficacy in non‑small cell lung cancer
- Trials targeting triple‑negative breast cancer and other aggressive subtypes
These studies aim to personalize cancer care and extend survival for patients with limited treatment options.
Nervous System Diseases
The facility is evaluating new oral therapies for migraine, focusing on both preventive and acute treatment strategies to reduce headache frequency and severity.
- Preventive medication trial measuring reduction in monthly migraine days
- Acute efficacy study of an oral agent for rapid pain relief
- Quality‑of‑life assessments in participants with chronic migraine
Successful outcomes could offer patients alternatives when existing therapies are ineffective or poorly tolerated.
Miscellaneous Research
A subset of trials focuses on hematologic disorders and rare cancers, exploring combination treatment approaches to address disease progression.
- Combination of a JAK inhibitor with another agent for myelofibrosis
- Safety and early efficacy profiling of emerging oncology compounds
- Biomarker discovery studies in patients with myeloproliferative neoplasms
The interdisciplinary effort seeks to broaden therapeutic options for conditions with high unmet medical need.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Kartos Therapeutics Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MICS Centrum Medyczne Szczecin
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors | Regeneron Pharmaceuticals Inc. | Phase I/II | Not Recruiting | May 2024 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2019-04-30 | 2026-04-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.